| Revenue growth | 18% YoY growth; highest ever quarterly revenue. |
|---|---|
| Margins | EBITDA margin improved through operational leverage and business mix. |
| Demand visibility | Positive outlook for CDMO and Exports; TGx expected to bridge gaps. |
| Management confidence | High; citing 14 consecutive quarters of record revenue. |
Growth
Q1FY27 Revenue grew 18% YoY to INR 248 Cr. EBITDA (excl. ESOP) grew 26% to INR 34 Cr; PAT grew 37% to INR 25 Cr.
Outlook
Plant 6 commercialization on track for H1FY27. Target revenue capacity of INR 1,100 Cr once fully operational.
Risks
Trade Generics vertical impacted by discontinuation of codeine-based products. API price volatility remains a monitoring point.
Last quarter's promises, checked
Delivered
- Plant 6 mechanical completion → achieved (H1FY27 launch on track) (= BEAT)
- Revenue growth of 19% YoY for FY26 → delivered 19% (= BEAT)
- Maintain ROCE/ROE above 25% → sustained above 25% (= BEAT)
Partly delivered
- Fill codeine-based revenue loss with alternates → partially filled in Q4 (= PARTIAL)
Earnings Call Transcript filed with BSE, NSE: WINDLAS. Summary written with AI assistance from the document.
Windlas Biotech Ltd: key numbers
- Share price
- ₹1,102.55
- Market cap
- ₹2,314 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 34.8×Sector 50.4×
- Promoter holding
- 63.31%+1.41% QoQ
- FII holding
- 2.04%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Investor Presentation: Key Takeaways
Windlas Biotech reported Q1FY27 revenue of ₹248 Cr (18% YoY). Adjusted EBITDA and PAT grew 26% and 37% respectively, excluding ESOP costs, driven by CDMO expansion.
Windlas Biotech Q1 FY27 Results: Net Profit ₹17.7 Cr, Up 0.0% YoY
Windlas Biotech Ltd reported revenue from operations of ₹248.1 Cr (+18.1% YoY) and net profit of ₹17.7 Cr (+0.0% YoY) for Q1 FY27.
- Key figure
- Net profit ₹17.7 Cr · +0.0% YoY
Windlas Biotech Earnings Call: Key Takeaways
Windlas Biotech reported record FY26 revenue of ₹904cr (up 19% YoY) and highest post-listing EPS of ₹31.60. Management emphasized scalability, capital efficiency (ROCE/ROE >25%), and diversification into injectables and exports.
Windlas Biotech Earnings Call: Key Takeaways
Windlas Biotech reported record annual revenue of ₹904 Cr in FY26, a 19% YoY growth, driven by its CDMO vertical. The company maintained a strong net liquidity position of ₹251 Cr with zero net debt.
Windlas Biotech Q4 FY26 Results: Net Profit ₹16 Cr, Down 1.8% YoY
Windlas Biotech Ltd reported revenue from operations of ₹238.5 Cr (+17.7% YoY) and net profit of ₹16 Cr (-1.8% YoY) for Q4 FY26.
- Key figure
- Net profit ₹16 Cr · -1.8% YoY